The International Society for Influenza and other Respiratory Viruses held an Antiviral Group conference in June, 2015.
This report covers oral presentations, including therapies against influenza and respiratory syncytial virus infections.
Therapies for rhinovirus, MERS and SARS coronavirus infections were also topics at the conference.
Some speakers focused on monoclonal antibodies as therapeutics and antibody-dependent enhancement of disease.
The importance of suitable clinical trial endpoints and regulatory issues were also discussed.